600993.SHG Mayinglong Pharmaceutical Group Co Ltd
- Market cap
- CNY 10.8B
- P/E
- 18.1x
- P/B
- 2.38x
- ROE
- 14.9%
- Dividend yield
- 2.51%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600993.SHG undervalued?
Graham number600993.SHG trades 38.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mayinglong Pharmaceutical Group Co Ltd fundamental analysis
No fundamental analysis for Mayinglong Pharmaceutical Group Co Ltd yet.
Mayinglong Pharmaceutical Group Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mayinglong Pharmaceutical Group Co Ltd
Mayinglong Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells Chinese and Western medicines in China and internationally. It operates through three segments: Pharmaceutical Manufacturing; Pharmaceutical Wholesale and Retail; and Medical Services. The company offers functional cosmetics, care products and food, Chinese herbal medicines, and medical devices. It also manufactures, processes, and sells pharmaceutical packaging materials, cosme…
Full company profileMayinglong Pharmaceutical Group Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Mayinglong Pharmaceutical Group Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.10B | 1.75B | 2.20B | 2.71B | 2.79B | 3.39B | 3.53B | 3.14B | 3.73B | 3.87B | 3.95B |
| Gross Profit | 760M | 876M | 991M | 1.11B | 1.10B | 1.37B | 1.49B | 1.31B | 1.73B | 1.90B | 1.81B |
| Operating Income | 271M | 366M | 193M | 425M | 500M | 550M | 556M | 537M | 667M | 670M | 796M |
| EBITDA | 322M | 404M | 233M | 465M | 541M | 601M | 622M | 591M | 709M | 811M | 839M |
| Net Income | 250M | 320M | 176M | 360M | 419M | 465M | 479M | 443M | 528M | 581M | 686M |
| EPS | 0.58 | 0.74 | 0.41 | 0.84 | 0.97 | 1.08 | 1.11 | 1.03 | 1.23 | 1.35 | 1.59 |
| Balance Sheet | |||||||||||
| Total Assets | 2.50B | 2.75B | 2.93B | 3.29B | 3.87B | 4.13B | 5.06B | 4.83B | 5.18B | 5.44B | 5.65B |
| Total Liabilities | 480M | 483M | 575M | 650M | 920M | 813M | 1.44B | 960M | 981M | 921M | 925M |
| Shareholders' Equity | 1.94B | 2.19B | 2.27B | 2.56B | 2.85B | 3.17B | 3.50B | 3.74B | 4.07B | 4.38B | 4.59B |
| Cash & Short-term Investments | 569M | 1.14B | 1.19B | 1.63B | 2.11B | 2.54B | 3.17B | 3.05B | 3.16B | 2.09B | 557M |
| Total Debt | 95.5M | 17.8M | 24.8M | 39.3M | 133M | 182M | 638M | 239M | 108M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 240M | 356M | 308M | 492M | 283M | 597M | 342M | 604M | 498M | 600M | - |
| Capital Expenditure | 65.2M | 41.9M | 25.0M | 46.4M | 45.4M | 65.1M | 75.0M | 248M | 204M | 119M | 42.1M |
| Free Cash Flow | 174M | 314M | 283M | 445M | 238M | 532M | 267M | 356M | 294M | 481M | 820M |
| Ratios | |||||||||||
| ROE | 12.9% | 14.6% | 7.8% | 14.1% | 14.7% | 14.6% | 13.7% | 11.9% | 13.0% | 13.3% | 14.9% |
| ROA | 10.0% | 11.6% | 6.0% | 11.0% | 10.8% | 11.3% | 9.5% | 9.2% | 10.2% | 10.7% | 12.1% |
| Net Profit Margin | 11.9% | 18.3% | 8.0% | 13.3% | 15.0% | 13.7% | 13.5% | 14.1% | 14.2% | 15.0% | 17.4% |
| Debt to Equity | 0.05x | 0.01x | 0.01x | 0.02x | 0.05x | 0.06x | 0.18x | 0.06x | 0.03x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Mayinglong Pharmaceutical Group Co Ltd dividends
- Dividend yield
- 2.51%
- Forward dividend
- 0.70 CNY
- Payout ratio
- 46.4%
- Ex-dividend date
- Aug 5, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 270M | 0.63 | 46.4% |
| 2024 | CNY 177M | 0.41 | 33.6% |
| 2023 | CNY 163M | 0.38 | 36.7% |
| 2022 | CNY 151M | 0.35 | 31.5% |
| 2021 | CNY 129M | 0.30 | 27.8% |
| 2020 | CNY 112M | 0.26 | 26.7% |
| 2019 | CNY 64.7M | 0.15 | 18.0% |
| 2018 | CNY 101M | 0.24 | 57.5% |
| 2017 | CNY 88.1M | 0.20 | 27.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 13:10 on Jul 21, 2015.
Who owns Mayinglong Pharmaceutical Group Co Ltd
- Insiders 35.35%
- Institutions 11.94%
- Public & others 52.71%
- Shares outstanding 431M
- Free float 274M
Mayinglong Pharmaceutical Group Co Ltd company profile
- Company name
- Mayinglong Pharmaceutical Group Co Ltd
- Ticker
- 600993.SHG
- ISIN
- CNE000001HN2
- Exchange
- Shanghai Stock Exchange
- Listed since
- Apr 23, 2004
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,544
- Fiscal year end
- December
- Address
- No. 100 Zhoujiawan, Wuhan, China, 430064
- Phone
- 86 27 8738 9583
- Website
- mayinglong.cn
About Mayinglong Pharmaceutical Group Co Ltd
Mayinglong Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells Chinese and Western medicines in China and internationally. It operates through three segments: Pharmaceutical Manufacturing; Pharmaceutical Wholesale and Retail; and Medical Services. The company offers functional cosmetics, care products and food, Chinese herbal medicines, and medical devices. It also manufactures, processes, and sells pharmaceutical packaging materials, cosmetics, and Chinese medicines; produces and sells health food; and offers class I and II medical devices, machinery, household goods, electronic products, daily necessities, hygiene products, and disinfection products, as well as road freight transportation services. In addition, the company is involved in the retail and wholesale of medical devices and medicines; imports raw and auxiliary materials, machinery and equipment, instruments and meters, spare parts and related technologies; and exports its products. Mayinglong Pharmaceutical Group Co., Ltd. was founded in 1582 and is headquartered in Wuhan, China.
Mayinglong Pharmaceutical Group Co Ltd management
8- Mr. Daonian ZhouGeneral Manager · born 1982
- Mr. Tao MaoFinancial Director · born 1977
- Mr. Ping An LiuDeputy GM & Director · born 1987
- Ms. Qian MaDeputy GM & Secretary to the Board of Directors · born 1982
- Mr. Zheng Jun TianDeputy General Manager · born 1969
- Mr. Zhi Qi SongDeputy General Manager · born 1976
- Mr. Wei ZhangDeputy General Manager · born 1978
- Peng LingHead of Accounting Agency